BACKGROUND D-dimer measurement is a promising tool in the exclusion of venous thrombosis. New D-dimer assays have been introduced, but need clinical validation. Our objective was to evaluate the clinical usefulness of four relatively new D-dimer assays and a classical ELISA in outpatients suspected for deep venous thrombosis. METHODS In 537 patients, participants in a large prospective management study using a clinical probability score and a D-dimer measurement (Tinaquant ® ), additional samples were taken for D-dimer measurement using the Asserachrom ELISA ® , the VIDAS New ® , the STA-LIA ® and the Miniquant ® assay. Performances of each test were calculated using clinical data during a 3-months follow-up. RESULTS Thrombosis was detected in 224 patients (42%). The area under the ROC curve was significantly higher for the Tina-quant ® as compared to the other assays. Using standard cut-off values, sensitivity, negative predictive value (NPV) and specificity of the Asserachrom ® were 97, 94 and 33% respectively. For the VIDAS New ® , values were 100, 96 and 8% respectively. The Tina-quant ® showed values of 99, 98 and 41% respectively and the STA-LIA ® 98, 95 and 32%. Values for the Miniquant ® were 95, 94 and 52%. CONCLUSIONS The D-dimer assays in our study all show a high sensitivity and negative predictive value, but none of the assays reached a NPV of > 98% at standard cut-off values. D-dimer assays with a low specificity still necessitate additional diagnostic tests in the majority of the patients.
INTRODUCTION
Measurement of the concentration of D-dimers is a promising tool in the non-invasive diagnostic management of patients suspected for having deep venous thrombosis (DVT). Retrospective analyses show a high sensitivity and negative predictive value of D-dimer for the exclusion of venous thromboembolism (VTE) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Two management studies have proven the safety of withholding anticoagulants in patients with a normal D-dimer and a normal initial ultrasonography (14;15) . Various combinations of pretest clinical probability scores and a normal D-dimer test or even a normal Ddimer alone have been suggested to be accurate enough for the exclusion of VTE (8;16-19) . However, the choice for a diagnostic management strategy depends largely upon the reliability of the D-dimer test. Many D-dimer assays are available. The classical enzyme linked immunosorbent assays (ELISA) are considered to be the golden standard in determining D-dimer (1;2;4-7;9;13;20;21), but they are time-consuming and not suitable for emergency use. The early latex assays have too little sensitivity to be used in clinical practice (1;22) and are replaced by newer latex assays with improved sensitivity and negative predictive value (5;6;10;12;13;16;17; [23] [24] [25] . The negative predictive value and the sensitivity of the D-dimer assay represent its safety in the exclusion of thrombosis in case of a normal Ddimer. The specificity reflects its clinical usefulness from an economical point of view. A low specificity, which is the result of a lot of false-positive test results, still implies additional diagnostic procedures in the majority of the patients. The purpose of this study is to evaluate the accuracy in terms of sensitivity and negative predictive value and the clinical usefulness in terms of specificity of four relatively new different D-dimer assays (VIDAS New ® , Tinaquant ® , STA-LIA ® and Miniquant ® ) and a classical ELISA in symptomatic outpatients suspected for DVT.
PATIENTS AND METHODS

Patients
In total, 537 eligible patients entered the current study. Exclusion criteria were pregnancy, previous deep venous thrombosis in the ipsilateral leg without documentation of recanalisation, a concomitant clinical suspicion of pulmonary embolism (PE), the use of unfractionated heparin, low molecular weight heparin or any form of oral anticoagulant in the past month, geographic impossibility for follow-up and life expectancy less than 3 months. The patients participated in a prospective multi-centre cohort study in outpatients with suspected DVT (26) and belonged to two of the four participating centres. Patients were categorized according to their D-dimer concentration (using the Tina-quant ® D-dimer assay) and their clinical probability score, according to Wells et al (27) . In patients with a normal Ddimer concentration and a non-high clinical score, no further testing was done. Patients with a normal D-dimer concentration and a high clinical score underwent a single compression ultrasonography (CUS). In case of an abnormal D-dimer concentration, serial CUS was performed. Primary outcome was the development of venous thromboembolism (DVT or PE) during a 3-months follow-up period. For detection of DVT, ultrasonography using real-time B-mode with compression was done with a 7.5 MHz and/or a 5.0 MHz transducer. Two areas of the leg were examined: the common femoral vein at the inguinal ligament and the popliteal vein at the knee-joint line traced down to the point of the trifurcation of the calf veins. Veins were scanned in the transverse plane only. Lack of compressibility was the sole criterion for an abnormal result; a vein was considered fully compressible if no residual lumen was seen. If a patient was suspected for PE after entering the prospective management study, a ventilation-perfusion scintigraphy was performed using routine methods. A normal scintigraphy ruled out PE, where a high probability scan confirmed the diagnosis. An intermediate probability scintigraphy was followed by pulmonary angiography.
Statistics
Sensitivity, negative predictive value (NPV) and specificity of the five Ddimer assays were calculated in relation to the results of the clinical outcomes, i.e. having venous thromboembolism at presentation or during follow-up. For calculation of 95% confidence intervals (CI), the exact binomial method was used. The Fisher's exact test was used for comparison of the sensitivity, NPV and specificity between the D-dimer assays. Receiver Operator Characteristics (ROC) curves were constructed by plotting sensitivity (true positive fraction) versus 1-specificity (false positive fraction) using Analyse-it ® Software for Microsoft Excel (Leeds, United Kingdom). The area under the curve (AUC) was then calculated and compared using the Hanley and McNeil method (28) . Agreement between two methods to classify a patient having a negative or positive test result was estimated by calculation of the kappa coefficient: a value of > 0.81 represents an excellent concordance, 0.80-0.61 a good concordance, 0.60-0.41 a moderate concordance, 0.40-0.21 a mediocre concordance, 0.20-0 a poor concordance and < 0 very poor concordance (29) .
RESULTS
The study population consisted of 537 patients. VTE was diagnosed in 224 patients (prevalence 42%): 210 patients had DVT at presentation, 11 patients had DVT detected by the second CUS, and three developed VTE during follow-up (one DVT and two PE). Both cases of PE were detected by ventilation-perfusion scintigraphy. Figure 1 shows the ROC curves displaying sensitivity and specificity for the different D-dimer assays at different cut-off levels. Using the Asserachrom ® ELISA as the reference test, the AUC of the VIDAS New ® , STA-LIA ® and Miniquant ® assays were not different (p=0.6, p=0.8 and p=0.1 respectively) ( Table 1 ). The AUC of the Tina-quant ® was significantly higher compared with the other assays; p=0.003 for comparison with the Asserachrom ® , p=0.004 with the VIDAS New ® , p<0.0001 with the STA-LIA ® and p=0.01 with the Miniquant ® . The performance of the different D-dimer assays is given in Table 2 , showing sensitivity, NPV and specificity with 95% confidence intervals according to different cut-off values for each assay. Given the cut-off values as recommended by the manufacturers, all D-dimer assays had a sensitivity of 95% or higher and a NPV of 94% or higher. The highest NPV (98%) was seen with the Tina-quant ® ; this was not significantly different as compared to the Asserachrom ® (p=0.08), the VIDAS New ® (p=0.4) and the STA-LIA ® (p=0.2), but higher as compared to the Miniquant ® (p=0.047). The highest sensitivity (100%) was seen with the VIDAS New ® assay: this was not statistically different as compared to the Asserachrom ® (p=0.07), the Tinaquant ® (p=1.0) and the STA-LIA ® (p=0.2), but higher as compared to the Miniquant ® (p=0.006). Sensitivity of the Miniquant ® (95%) was lower as compared to the Tina-quant ® (p=0.02). By changing the cut-off values, only in the Tina-quant ® a NPV of 100% could be reached. Slight (not statistically significant) improvements of the NPV were seen in the Asserachrom ® and STA-LIA ® assays by lowering the cut-off values, but they led to significant reductions in specificity. A low specificity was seen for the VIDAS New ® D-dimer assay: its specificity of 8% was lower than the other D-dimer assays that showed values of 32-52% (p<0.0001 when compared to the Asserachrom ® ). The number of patients with a negative VIDAS New ® D-dimer test result was 27/537 as compared to 110/537 negative Asserachrom ® tests (p<0.0001), 131/537 negative Tina-quant ® 6 chapter tests (p<0.0001), 106/537 negative STA-LIA ® tests (p<0.0001) and 174/537 negative Miniquant ® tests (p<0.0001). Table 3 shows the kappa coefficients between the 5 D-dimer assays. The concordance of the Asserachrom ® with the Tina-quant ® and the STA-LIA ® is good, with the Miniquant ® moderate and with the VIDAS New ® mediocre. The concordance of the VIDAS New ® with the other D-dimer assays was mediocre or worse. Concordance between the Tina-quant ® , STA-LIA ® and Miniquant ® was good. 
DISCUSSION
The diagnostic strategy in patients suspected for DVT or PE is being challenged by the development of highly sensitive D-dimers and the revival of the pretest clinical probability score. Recent studies have demonstrated the safety of withholding anticoagulant treatment in patients with a normal D-dimer and a normal single ultrasound (14;15) . Even the combination of a low clinical score and a normal D-dimer concentration can be considered a safe strategy to exclude thrombosis and to withhold anticoagulant therapy in patients suspected for venous thromboembolism (8;15-17;19;26;30-32) . When trying to replace accepted strategies like venography or serial ultrasound, their failure rates of, respectively, 1.3% (33) and 0.6-0.7% (34;35) may not be exceeded by the new diagnostic strategy. Therefore, a highly sensitive D-dimer test is mandatory for the exclusion of thrombosis in every new diagnostic strategy. Differences between D-dimer assays are thought to be caused by antibody specificity, especially concerning the preference for high-or low molecular weight fibrin derivates and for crosslinked and non-crosslinked fibrin derivates (36) . Other causes of discrepancies between D-dimer assays are time-dependence of neo-epitope expression in the course of fibrin formation and dissolution, assay format, purity or heterogeneity of the calibrator, matrix effects of plasma on epitope presentation and interference by irrelevant analytes (37) . In our study, ROC curve analysis showed a significantly higher AUC for the Tina-quant ® D-dimer assay as compared to the other four assays. At standard cut-off values, the Tina-quant ® also had the highest NPV with 98% (although not statistically different), with a high sensitivity of 99%. The performance of the Tina-quant ® in our study was comparable with previous reports (1;5;13). Using standard cut-off values, the Miniquant ® reached a sensitivity of 95% with a NPV of 94%, which is comparable with previous reports (38) (39) (40) . It had significant lower values of sensitivity and NPV as compared to the Tina-quant ® and a significant lower sensitivity as compared to the VIDAS New ® . Results of the STA-LIA ® assay showed a high sensitivity of 98% and NPV of 95%. This is higher than a previous report that found a sensitivity of 89% and NPV of 86% (41) but comparable with other reports (42) (43) (44) . The VIDAS New ® had an excellent sensitivity of 100% and a NPV of 96%, which was better than a previous report (45) but comparable with a study from de Moerloose et al (46) .
chapter
It is well known that the D-dimer tests have positive results in case of various co-morbid conditions, such as infections and malignancy. Due to these frequent false-positive test results, the specificity of the D-dimer is low. It is the specificity that determines the usefulness of the D-dimer as an exclusion criterion for thrombosis. A low specificity of a D-dimer implies that CUS will still be necessary in the majority of the patients. Although the sensitivity and NPV of the VIDAS New ® were high, a remarkably low specificity of 8% was found. This low specificity is in disagreement with two previous reports on the VIDAS New ® (45;46) that found a specificity of 42% and 33% respectively at the same cut-off level. Furthermore, the kappa coefficients of the VIDAS New ® compared to the other four assays were mediocre to poor. This is in disagreement with the kappa coefficients for the original VIDAS compared to the STA-LIA ® , Asserachrom ® and Tinaquant ® as found by van der Graaf et al (13) . As the VIDAS New ® assay is fully automated and not dependent on technician skills, it is not likely that variables in the analytic process have lead to the large number of false-positive results in our study. A previous report has seen no effect of transportation or storage at room temperature on the results of the VIDAS ® D-dimer assay (47) . We showed recently that freezing of samples or type of chemical analyser had no influence on D-dimer concentration (48) . A considerable improvement of the performance of the VIDAS New ® was achieved after raising the cut-off level to 1.0 FEU mg/L, resulting in a sensitivity of 98%, a NPV of 96%, and a specificity of 29%. The D-dimer assays in our study all showed generally high sensitivity and NPV. In general, the sensitivity could be improved by lowering the cut-off values, but the subsequent decrease in specificity makes the assays less useful in clinical practice. Despite changes in cut-off values none of the tests reached a NPV of > 98%, except for the Tina-quant ® . Using standard cutoff values, none of the tests reached a NPV of > 98%. When the use of D-dimer is restricted to patients with a low clinical probability score only, it has been shown for the SimpliRed ® and Tina-quant ® assay that the NPV of the D-dimer assay will further increase (18;26;30) . It is therefore to be expected that the combination of a clinical probability score and the other D-dimer tests from our study will also increase the NPV and be a safe strategy to exclude DVT in outpatients.
In conclusion, the D-dimer assays in our study all show a high sensitivity and negative predictive value. However, using standard cut-off values, none of the assays reached a NPV of > 98%. For exclusion of DVT, we therefore recommend combining the D-dimer assay with other non-invasive tests in order to reach failure rates less than 1.0%. The use of D-dimer assays with a very low specificity might not be worthwhile from an economical point of view, as a positive test will necessitate additional testing in the majority of the patients.
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